Blood Levels of Ammonia and Carnitine in Patients Treated with Valproic Acid: A Meta-analysis

키워드

참고문헌 (60)

1. Monti B, "Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection", Curr Mol Pharmacol, 2, pp.95~109 (2009)
2. Yokoyama S, "Association between the serum carnitine level and ammonia and valproic acid levels in patients with bipolar disorder", Ther Drug Monit, 42, pp.766~770 (2020)
3. Engel AG, "Carnitine metabolism and inborn errors", J Inherit Metab Dis, 7(Suppl 1), pp.38~43 (1984)
4. Okumura A, "Serum carnitine levels of children with epilepsy : related factors including valproate", Brain Dev, 41, pp.516~521 (2019)
5. Abbasnezhad A, "Effect of L-carnitine on liver enzymes and biochemical factors in hepatic encephalopathy : a systematic review and meta-analysis", J Gastroenterol Hepatol, 34, pp.2062~2070 (2019)
6. Hamed SA, "The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate : relationship to blood carnitine status", Epilepsy Res, 86, pp.32~41 (2009)
7. Nakajima Y, "Evaluation of valproate effects on acylcarnitine in epileptic children by LC-MS", MS, 2011, pp.33, 816~823
8. Knobloch K, "Preferred reporting items for systematic reviews and meta-analyses(PRISMA)statement and publication bias", J Craniomaxillofac Surg, 39, pp.91~92 (2011)
9. Maldonado C, "Carnitine and", or acetylcarnitine deficiency as a cause of higher levels of ammonia, 2016, pp.2016, 2920108~
10. Yamamoto Y, "Risk factors for hyperammonemia in pediatric patients with epilepsy", Epilepsia, 54, pp.983~989 (2013)
11. Castro-Gago M, "Serum biotinidase activity in children treated with valproic acid and carbamazepine", J Child Neurol, 25, pp.32~35 (2010)
12. Agarwal R, "Hyperammonemia and hepatic status during valproate therapy", Indian J Clin Biochem, 24, pp.366~369 (2009)
13. Verrotti A, "Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs", Int J Clin Lab Res, 29, pp.36~40 (1999)
14. Hirose S, "Valproate therapy does not deplete carnitine levels in otherwise healthy children", Pediatrics, 101, pp.E9~ (1998)
15. Altunbaşak S, "Asymptomatic hyperammonemia in children treated with valproic acid", J Child Neurol, 12, pp.461~463 (1997)
16. Thom H, "Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs", Dev Med Child Neurol, 33, pp.795~802 (1991)
17. Beghi E, "Valproate, carnitine metabolism, and biochemical indicators of liver function. Collaborative Group for the Study of Epilepsy", Epilepsia, 31, pp.346~352 (1990)
18. Komatsu M, "Valproate-associated hyperammonemia and DL-carnitine supplement", Kobe J Med Sci, 33, pp.81~87 (1987)
19. Kugoh T, "Blood ammonia level during valproic acid therapy", Jpn J Psychiatry Neurol, 40, pp.663~668 (1986)
20. Farrell K, "Free and total serum valproate concentrations : their relationship to seizure control, liver enzymes and plasma ammonia in children", Can J Neurol Sci, 13, pp.252~255 (1986)
21. Ratnaike RN, "Hyperammonaemia and hepatotoxicity during chronic valproate therapy : enhancement by combination with other antiepileptic drugs", Br J Clin Pharmacol, 22, pp.100~103 (1986)
22. Haidukewych D, "Chronic valproic acid therapy and incidence of increases in venous plasma ammonia", Ther Drug Monit, 7, pp.290~294 (1985)
23. Ohtani Y, "Carnitine deficiency and hyperammonemia associated with valproic acid therapy", J Pediatr, 101, pp.782~785 (1982)
24. Qiliang L, "Carnitine deficiency in Chinese children with epilepsy on valproate monotherapy", Indian Pediatr, 55, pp.222~224 (2018)
25. Cansu A, "Analysis of acylcarnitine levels by tandem mass spectrometry in epileptic children receiving valproate and oxcarbazepine", Epileptic Disord, 13, pp.394~400 (2011)
26. Anil M, "Serum and muscle carnitine levels in epileptic children receiving sodium valproate", J Child Neurol, 24, pp.80~86 (2009)
27. Zelnik N, "Vigabatrin, lamotrigine, topiramate and serum carnitine levels", Pediatr Neurol, 39, pp.18~21 (2008)
28. Werner T, "Effects of valproate on acylcarnitines in children with epilepsy using ESI-MS", MS, 2007, pp.48, 72~76
29. Castro-Gago M, "Serum carnitine levels in epileptic children before and during treatment with valproic acid, carbamazepine, and phenobarbital", J Child Neurol, 13, pp.546~549 (1998)
30. Hiraoka A, "Reduction in blood free carnitine levels in association with changes in sodium valproate(VPA)disposition in epileptic patients treated with VPA and other anti-epileptic drugs", Biol Pharm Bull, 20, pp.91~93 (1997)
31. Zelnik N, "Reduced carnitine and antiepileptic drugs : cause relationship or co-existence?", Acta Paediatr, 84, pp.93~95 (1995)
32. Riva R, "Carnitine disposition before and during valproate therapy in patients with epilepsy", Epilepsia, 34, pp.184~187 (1993)
33. Hug G, "Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children", J Pediatr, 119, pp.799~802 (1991)
34. Opala G, "The effect of valproic acid on plasma carnitine levels", Am J Dis Child, 145, pp.999~1001 (1991)
35. Matsumoto K, "Fluorometric determination of carnitine in serum with immobilized carnitine dehydrogenase and diaphorase", Clin Chem, 36, pp.2072~2076 (1990)
36. Melegh B, "L-carnitine replacement therapy in chronic valproate treatment", Neuropediatrics, 21, pp.40~43 (1990)
37. Rodriguez-Segade S, "Carnitine deficiency associated with anticonvulsant therapy", Clin Chim Acta, 181, pp.175~181 (1989)
38. Melegh B, "Effect of chronic valproic acid treatment on plasma and urine carnitine levels in children : decreased urinary excretion", Acta Paediatr Hung, 28, pp.137~142 (1987)
39. Morita J, "Hypocarnitinemia in the handicapped individuals who receive a polypharmacy of antiepileptic drugs", Neuropediatrics, 17, pp.203~205 (1986)
40. Laub MC, "Serum carnitine during valproic acid therapy", Epilepsia, 27, pp.559~562 (1986)
41. Redden L, "Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder", J Child Adolesc Psychopharmacol, 19, pp.83~89 (2009)
42. Paganini M, "Venous blood ammonia concentrations in adult epileptic patients are increased by treatment with valproic acid", Acta Neurol(Napoli), 6, pp.442~446 (1984)
43. Van Wouwe JP, "Carnitine deficiency during valproic acid treatment", Int J Vitam Nutr Res, 65, pp.211~214 (1995)
44. Duman B, "Risk factors for valproic acid induced hyperammonemia and its association with cognitive functions", Gen Hosp Psychiatry, 59, pp.67~72 (2019)
45. Günaydın YK, "Antiepileptic drug poisoning : three-year experience", Toxicol Rep, 2, pp.56~62 (2014)
46. Tseng YL, "Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy", Medicine(Baltimore), 93, pp.e66~ (2014)
47. Sharma S, "Blood ammonia levels in epileptic children on 2 dose ranges of valproic acid monotherapy : a cross-sectional study", J Child Neurol, 26, pp.109~112 (2011)
48. Moreno FA, "Carnitine levels in valproic acid-treated psychiatric patients : a cross-sectional study", J Clin Psychiatry, 66, pp.555~558 (2005)
49. Patsalos PN, "The prevalence of valproic-acid-associated hyperammonaemia in patients with intractable epilepsy resident at the Chalfont centre for epilepsy", J Epilepsy, 6, pp.228~232 (1993)
50. Kondo T, "Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?", Epilepsia, 33, pp.550~554 (1992)
51. Laub MC, "Nutritional influence on serum ammonia in young patients receiving sodium valproate", Epilepsia, 27, pp.55~59 (1986)
52. Williams CA, "Valproic acidinduced hyperammonemia in mentally retarded adults", Neurology, 34, pp.550~553 (1984)
53. Ando M, "Association between the blood concentrations of ammonia and carnitine", amino acid of schizophrenic patients treated with valproic acid, 2017, pp.11, 19~
54. Goto S, "Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients", J Pharm Pharmacol, 60, pp.267~272 (2008)
55. Verbiest HB, "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma", Acta Neurol Scand, 86, pp.275~279 (1992)
56. Aires CC, "New insights on the mechanisms of valproate-induced hyperammonemia : inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA", J Hepatol, 55, pp.426~434 (2011)
57. Foster DW, "The role of the carnitine system in human metabolism", Ann N Y Acad Sci, 1033, pp.1~16 (2004)
58. Farkas V, "Inhibition of carnitine biosynthesis by valproic acid in rats--the biochemical mechanism of inhibition", Biochem Pharmacol, 52, pp.1429~1433 (1996)
59. Balduzzi S, "How to perform a meta-analysis with R : a practical tutorial", Evid Based Ment Health, 22, pp.153~160 (2019)
60. Croux C, "Influence functions of the Spearman and Kendall correlation measures", Stat Methods Appl, 19, pp.497~515 (2010)

관련 논문AI추천